ArticleClinical rheumatology2025
Long-term clinical prognosis of anti-aminoacyl-tRNA synthetase antibodies and interstitial lung disease.
Article in Clinical rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Treatment Response and Safety Profile of Nintedanib in Connective Tissue Disease-Associated Interstitial Lung Disease: A Retrospective Observational Study.Mediterranean journal of rheumatology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAnti-aminoacyl tRNA synthetase (anti-ARS) antibody is the most common myositis-specific antibody subtype. Anti-ARS antibody-positive myositis is often complicated by interstitial lung disease (ILD), but the clinical progression of anti-ARS antibody-positive ILD (ARS-ILD) remains unclear.
methodA prospectively collected, single center longitudinal myositis database was used to retrospectively investigate 131 patients with ARS-ILD based on subtypes of anti-ARS antibodies (Jo-1, PL-7, PL-12, EJ, OJ, and KS). We investigated the occurrence and associated risk factors for pulmonary events, including lung transplantation and pulmonary death, as well as overall mortality at both 5 and 10 years.
resultsThis cohort included those with myositis (n = 97), anti-synthetase syndrome without myositis (n = 17), and other connective tissue diseases (n = 17). In a 5-year period, the overall mortality rate and incidence of pulmonary events were both 15%. Across a 10-year timespan, the overall mortality rate increased to 28%, with pulmonary events observed in 24% of cases. A multivariate analysis during the 5-year follow-up, identified poor prognostic factors for overall mortality included dysphagia, dry eyes, usual interstitial pneumonia (UIP) pattern, and the presence of anti-PL-7 antibody. In the 10-year follow-up, dysphagia, diffusing capacity for carbon monoxide (DLCO)%, and anti-PL-7 antibody were associated with increased mortality. Risk factors for pulmonary events at 5 years were DLCO% and UIP pattern, while at 10 years, dysphagia and DLCO% were significant poor prognosis factors.
conclusionsAnti-PL-7 antibodies, dysphagia, UIP pattern, and decreased DLCO% predicted poor outcomes in ARS-ILD, indicating the importance of comprehensive risk assessment. Key Points • In patients with ARS-ILD, anti-PL-7 antibodies are associated with risk of all-cause mortality, and evaluation of antibody subtypes in prognosis is important. • The UIP pattern affected prognosis and pulmonary events within the first 5 years. • Dysphagia is the strongest predictor of all-cause mortality and pulmonary events, and management strategies in patients with ARS-ILD are important.
Indexed as
Identifiers
40571884What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.